TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7920128

Group type: EXPERIMENTAL
Intervention: Serum cholesterol concentration
Number of subjects: 22432

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 22432

Group type: EXPERIMENTAL
Intervention: Frequent use of alcohol
Number of subjects: 22432
Study: 3363288

Group type: EXPERIMENTAL
Intervention: Single intraduodenal dose of camostate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Daily ingestion of camostate for 5 days
Number of subjects: 8
Study: 435882

Group type: EXPERIMENTAL
Intervention: Chenic acid (14‐16 mg/kg/day) administered at bedtime
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chenic acid (14‐16 mg/kg/day) administered in the morning
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chenic acid (14‐16 mg/kg/day) administered at mealtimes
Number of subjects: 16
Study: 30351172

Group type: EXPERIMENTAL
Intervention: Relaxation Meditation Tape (RM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined RM + Relaxation Lighting (RM+L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Music Tape (M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined Music + Relaxation Lighting (M+L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study: 28291511

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (2 mg/mL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (2 mg/mL) with morphine (1 mg/mL)
Number of subjects: 23
Study: 26640405

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 45
Study: 23603619

Group type: EXPERIMENTAL
Intervention: Low-volume strength training (1 set, twice weekly for 13 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-volume strength training (3 sets, twice weekly for 13 weeks)
Number of subjects: 20
Study: 21322768

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS) for 3 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non‐intervention control
Number of subjects: 39
Study: 19958108

Group type: EXPERIMENTAL
Intervention: Phenylephrine 10% and tropicamide 1% (group 0: type 2 diabetic patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 1% (group 1: non-diabetic patients)
Number of subjects: 50
Study: 17540020

Group type: EXPERIMENTAL
Intervention: Perturbation-based training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (flexibility/relaxation training)
Number of subjects: 30
Study: 15044749

Group type: EXPERIMENTAL
Intervention: SH U 555 C (40 micromol Fe/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SH U 555 C (5 micromol Fe/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SH U 555 C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study: 11500288

Group type: EXPERIMENTAL
Intervention: Administration of open-ended test questions by computer
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Administration of open-ended test questions by paper-and-pencil
Number of subjects: 1194
Study: 9929147

Group type: EXPERIMENTAL
Intervention: Radiation therapy with external dose > 60 Gy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 252
Study: 7917735

Group type: COMPARATOR
Intervention: suxamethonium 0.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: suxamethonium 3.0 mg kg‐1
Number of subjects: 30
Study: 3045113

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30649970

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 120
Study: 31023863

Group type: COMPARATOR
Intervention: 80 mg/m2 solvent-based paclitaxel (PACL80/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg/m2 nab-paclitaxel (NAB100/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg/m2 nab-paclitaxel (NAB150/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg/m2 nab-paclitaxel (NAB150/2w)
Number of subjects: 0
Study: 28340118

Group type: EXPERIMENTAL
Intervention: Group Music Therapy (GMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-Directed Music Listening (SDML)
Number of subjects: 100
Study: 26099758

Group type: EXPERIMENTAL
Intervention: Supraclavicular blockade
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infraclavicular blockade
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interscalene blockade
Number of subjects: 60
Study: 24303975

Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg twice a day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21142269

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of paroxetine and itraconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18055020

Group type: EXPERIMENTAL
Intervention: Subjects reporting dimness (at least some of the time)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Subjects never noting dimness
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Depressed individuals (CES-D > or = 16)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Total CES-D score and degree of reported dimness (0-3)
Number of subjects: 213
Study: 17925516

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/d)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 15474136

Group type: EXPERIMENTAL
Intervention: Information leaflet plus an appointment with an alcohol health worker
Number of subjects: 599

Group type: COMPARATOR
Intervention: Information leaflet (control group)
Number of subjects: 599
Study: 11114448

Group type: EXPERIMENTAL
Intervention: Multi-axis graph representation of joint rotations
Number of subjects: 15
Study: 9022117

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.08%
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.5%
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 7910235

Group type: EXPERIMENTAL
Intervention: Increased pressure on tissue due to inappropriate sensor fixation (50 mm Hg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venous congestion at 30 mm Hg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venous congestion at 40 mm Hg
Number of subjects: 20
Study: 3598226

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon (IFN; 9 X 10(6) U per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29623574

Group type: EXPERIMENTAL
Intervention: Visionaire PSI system (Smith and Nephew, Memphis, TN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study: 26773446

Group type: EXPERIMENTAL
Intervention: IDegAsp+IAsp
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDet+IAsp
Number of subjects: 0
Study: 26165865

Group type: EXPERIMENTAL
Intervention: Compression of the 4th ventricle
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham compression of the fourth ventricle
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 81
Study: 23805899

Group type: EXPERIMENTAL
Intervention: Trophic enteral feeding
Number of subjects: 174

Group type: COMPARATOR
Intervention: Full enteral feeding
Number of subjects: 174
Study: 21923988

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS) every 14 days until 33+6 weeks or birth
Number of subjects: 1858

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (ACS)
Number of subjects: 1858
Study: 18819870

Group type: EXPERIMENTAL
Intervention: Delay time of 8 seconds (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delay time of 10 seconds (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delay time of 4 seconds (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delay time of 6 seconds (Group B)
Number of subjects: 60
Study: 16707412

Group type: EXPERIMENTAL
Intervention: Liquid etanercept (50 mg/mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reconstituted lyophilized etanercept (25 mg/mL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Liquid etanercept
Number of subjects: 36
Study: 12702524

Group type: EXPERIMENTAL
Intervention: Arm A (cisplatin 25 mg/m(2) day 1, weekly for 9 weeks, irinotecan 90 mg/m(2) day 1, on weeks 1, 3, 5, 7 and 9, etoposide 60 mg/m(2) days 1‐3, on weeks 2, 4, 6, 8)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arm B (cisplatin 60 mg/m(2) day 1, irinotecan 60 mg/m(2) days 1, 8, 15, etoposide 50 mg/m(2) days 1‐3, every 4 weeks for four cycles)
Number of subjects: 60
Study: 11197053

Group type: EXPERIMENTAL
Intervention: 3 micrograms CIFN three times a week for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 micrograms CIFN three times a week for 24 weeks
Number of subjects: 0
Study: 8832006

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells with purged or unpurged bone marrow (BM)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Autologous hematopoietic stem cells with unpurged peripheral blood stem cells (PBSCs)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells with purged or unpurged BM
Number of subjects: 153

Group type: COMPARATOR
Intervention: Autologous hematopoietic stem cells with unpurged PBSCs
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Patients receiving BM
Number of subjects: 153

Group type: COMPARATOR
Intervention: Patients receiving PBSC +/‐ BM
Number of subjects: 153

Group type: COMPARATOR
Intervention: Patients receiving unpurged PBSC alone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Patients receiving purged BM
Number of subjects: 153

Group type: COMPARATOR
Intervention: Patients receiving unpurged PBSCs
Number of subjects: 153
Study: 1399073

Group type: EXPERIMENTAL
Intervention: Hydron root canal fillings
Number of subjects: 74

Group type: COMPARATOR
Intervention: gutta‐percha/AH‐26 root canal fillings
Number of subjects: 74
Study: 4057034

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg intramuscularly as a pre-anesthetic
Number of subjects: 39

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 39
Study: 31644585

Group type: EXPERIMENTAL
Intervention: 30-hour Training Course on Emotional Intelligence (TCEI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 29985964

Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone treatment
Number of subjects: 179

Group type: COMPARATOR
Intervention: No dexamethasone exposure (control group)
Number of subjects: 179
Study: 27129624

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 24803825

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus thalidomide
Number of subjects: 86

Group type: COMPARATOR
Intervention: Radiotherapy alone (non-drug group)
Number of subjects: 86
Study: 22044195

Group type: EXPERIMENTAL
Intervention: Pomegranate Seed Oil (PSO) 400 mg capsules twice daily for 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo capsules twice daily for 4 weeks
Number of subjects: 51
Study: 20488410

Group type: EXPERIMENTAL
Intervention: Overlapping sirolimus-eluting stents (SES)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overlapping paclitaxel-eluting stents (PES)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overlapping zotarolimus-eluting stents (ZES)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overlapping bare-metal stents (BMS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonoverlapping bare-metal stents (BMS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonoverlapping drug-eluting stents (DES)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overlap segments of drug-eluting stents (DES)
Number of subjects: 77
Study: 18630591

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment with 'Xiusanzhen' technique.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (Duxil, 40 mg/time, 2 times/d for 10 weeks).
Number of subjects: 60
Study: 15951469

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Body surface area-based dosing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Body surface area alone
Number of subjects: 102
Study: 12898883

Group type: EXPERIMENTAL
Intervention: Psoriatic patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study: 10715370

Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen and misoprostol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo and misoprostol
Number of subjects: 150
Study: 7854523

Group type: EXPERIMENTAL
Intervention: HIV-positive subjects
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: HIV-positive subjects with CD4 < or = 200
Number of subjects: 207
Study: 1952856

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg every 12 h orally for 7 to 10 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Parenteral aminoglycoside for 7 to 10 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Aminoglycosides
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and aminoglycoside
Number of subjects: 65
Study: 7064026

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg after metoclopramide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atropine 0.6 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg after atropine
Number of subjects: 8
Study: 30295721

Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training (IMT) for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 29108407

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 grams intravenously for 20 minutes before anesthesia)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 98
Study: 26914296

Group type: EXPERIMENTAL
Intervention: 2 g of magnesium sulphate intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 25702375

Group type: EXPERIMENTAL
Intervention: Wheelchair Self-Efficacy Enhanced for Use (WheelSeeU) training
Number of subjects: 40
Study: 22269160

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day after up-titration over 4 weeks)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: COMPARATOR
Intervention: Memantine and Placebo (comparison)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Patients not treated with acetyl cholinesterase inhibitors (AChEIs)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 278

Group type: COMPARATOR
Intervention: Memantine and Placebo (correlation)
Number of subjects: 278
Study: 20680188

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/d for 4 weeks
Number of subjects: 24
Study: 17244775

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted cumulative area under the curve model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical subgroup analysis
Number of subjects: 0
Study: 15208467

Group type: COMPARATOR
Intervention: QI-Therapy
Number of subjects: 1176

Group type: COMPARATOR
Intervention: QI-Meds
Number of subjects: 1176
Study: 12350480

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325
Study: 10546008

Group type: EXPERIMENTAL
Intervention: Immediate assay group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 7606946

Group type: EXPERIMENTAL
Intervention: Music (M+)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (M-)
Number of subjects: 49
Study: 2229286

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14
Study: 860743

Group type: EXPERIMENTAL
Intervention: Sensory integrative therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 0
Study: 31124928

Group type: EXPERIMENTAL
Intervention: Benson relaxation method (BRM)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 634
Study: 29183393

Group type: EXPERIMENTAL
Intervention: Prophylactic penehyclidine inhalation
Number of subjects: 864

Group type: COMPARATOR
Intervention: Placebo (water for injection)
Number of subjects: 864
Study: 26380437

Group type: EXPERIMENTAL
Intervention: Qingyuan Shenghua Decoction (QSD), one dose per day for 1 week
Number of subjects: 60
Study: 24377215

Group type: EXPERIMENTAL
Intervention: Chen's needling therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional needling therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison between Chen's needling therapy and Conventional needling therapy
Number of subjects: 84
Study: 21943482

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including e-learning, team training, introduction of electronic alcohol based hand rub dispensers and performance feedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 16
Study: 19930855

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Combined glucose intolerance (CGI)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT)
Number of subjects: 590
Study: 16500485

Group type: EXPERIMENTAL
Intervention: Doppler tissue echocardiography-derived strain rate imaging
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (28 healthy volunteers; 20 women; 44 ± 10 years)
Number of subjects: 30
Study: 12937051

Group type: EXPERIMENTAL
Intervention: Phototherapy with turquoise fluorescent lamp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phototherapy with blue fluorescent lamp
Number of subjects: 0
Study: 12380408

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9529836

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms for 5 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 114
Study: 8039530

Group type: EXPERIMENTAL
Intervention: MK-0434 (0.1-100 mg)
Number of subjects: 0
Study: 2688711

Group type: EXPERIMENTAL
Intervention: High Flux Dialysis (HF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Dialysis (CD)
Number of subjects: 20
Study: 1002100

Group type: EXPERIMENTAL
Intervention: Contrapect (new antitussive principle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31677542

Group type: EXPERIMENTAL
Intervention: Osmometry
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pressure‐volume (P‐V) curves
Number of subjects: 6
Study: 28528395

Group type: EXPERIMENTAL
Intervention: Combined treatment of fractional CO2 laser therapy and hair growth factors
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hair growth factors alone
Number of subjects: 28
Study: 25122150

Group type: EXPERIMENTAL
Intervention: Tadalafil treatment
Number of subjects: 405
Study: 23638631

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate/dienogest (E2V/DNG)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Ethinylestradiol/norgestimate (EE/NGM)
Number of subjects: 409
Study: 22353406

Group type: EXPERIMENTAL
Intervention: Self-etching sealant (Enamel Loc)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional phosphoric acid-etched sealant (UltraSeal XT Plus)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Saliva contamination
Number of subjects: 52
Study: 19559235

Group type: EXPERIMENTAL
Intervention: EmBlocker (Neurosonix Ltd) activated for 1 minute (1.5 W/cm(2)) during seven selected aortic manipulations and for 10 minutes (0.5 W/cm(2)) intermittently after cross-clamp removal.
Number of subjects: 21
Study: 16430436

Group type: EXPERIMENTAL
Intervention: galyfilcon A lenses
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: lotrafilcon A lenses
Number of subjects: 56
Study: 15499291

Group type: EXPERIMENTAL
Intervention: Attenuation corrected (AC) studies
Number of subjects: 500

Group type: COMPARATOR
Intervention: Non-attenuation corrected (NAC) studies
Number of subjects: 500

Group type: COMPARATOR
Intervention: NAC studies
Number of subjects: 500
Study: 11707563

Group type: EXPERIMENTAL
Intervention: Liquid meal replacement containing lactose, fructose, and sucrose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Liquid meal replacement with oligosaccharides (sugar-free Slim-Fast)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Exchange diet plan (EDP)
Number of subjects: 75
Study: 9291756

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Suprasternal palpation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Roll test
Number of subjects: 10